Targeting Non-Coding RNAs for the Development of Novel Hepatocellular Carcinoma Therapeutic Approaches

被引:8
作者
Jesenko, Tanja [1 ]
Brezar, Simona Kranjc [1 ]
Cemazar, Maja [1 ,2 ]
Biasin, Alice [3 ]
Tierno, Domenico [4 ]
Scaggiante, Bruna [4 ]
Grassi, Mario [3 ]
Grassi, Chiara [5 ]
Dapas, Barbara [4 ]
Truong, Nhung Hai [6 ]
Abrami, Michela [3 ]
Zanconati, Fabrizio [7 ]
Bonazza, Deborah [7 ]
Rizzolio, Flavio [8 ,9 ]
Parisi, Salvatore [9 ,10 ]
Pastorin, Giorgia
Grassi, Gabriele [4 ]
机构
[1] Inst Oncol Ljubljana, Dept Expt Oncol, Zaloska 2, SI-1000 Ljubljana, Slovenia
[2] Univ Primorska, Fac Hlth Sci, Polje 42, SI-6310 Izola, Slovenia
[3] Trieste Univ, Dept Engn & Architecture, via Valerio 6, I-34127 Trieste, Italy
[4] Trieste Univ, Cattinara Univ Hosp, Dept Life Sci, Str Fiume 447, I-34149 Trieste, Italy
[5] Univ Trieste, Degree Course Med, I-34149 Trieste, Italy
[6] VNUHCM Univ Sci, Fac Biol & Biotechnol, Ho Chi Minh City 70000, Vietnam
[7] Univ Trieste, Cattinara Hosp, Dept Med Surg & Hlth Sci, Str Fiume 447, I-34149 Trieste, Italy
[8] Ctr Riferimento Oncol Aviano CRO IRCCS, Pathol Unit, I-33081 Aviano, Italy
[9] CaFoscari Univ Venice, Dept Mol Sci & Nanosyst, I-30172 Venice, Italy
[10] Univ Trieste, Doctoral Sch Mol Biomed, I-34149 Trieste, Italy
关键词
hepatocellular carcinoma; lifer fibrosis; micro interfering RNAs; long non-coding RNAs; circular RNAs; SUPPRESSES CELL-PROLIFERATION; CIRCULAR RNAS; UP-REGULATION; CANCER-CELLS; MICRORNA; EXPRESSION; PROMOTES; PROGRESSION; MIGRATION; PATHWAY;
D O I
10.3390/pharmaceutics15041249
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hepatocellular carcinoma (HCC) remains a global health challenge, representing the third leading cause of cancer deaths worldwide. Although therapeutic advances have been made in the few last years, the prognosis remains poor. Thus, there is a dire need to develop novel therapeutic strategies. In this regard, two approaches can be considered: (1) the identification of tumor-targeted delivery systems and (2) the targeting of molecule(s) whose aberrant expression is confined to tumor cells. In this work, we focused on the second approach. Among the different kinds of possible target molecules, we discuss the potential therapeutic value of targeting non-coding RNAs (ncRNAs), which include micro interfering RNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs). These molecules represent the most significant RNA transcripts in cells and can regulate many HCC features, including proliferation, apoptosis, invasion and metastasis. In the first part of the review, the main characteristics of HCC and ncRNAs are described. The involvement of ncRNAs in HCC is then presented over five sections: (a) miRNAs, (b) lncRNAs, (c) circRNAs, (d) ncRNAs and drug resistance and (e) ncRNAs and liver fibrosis. Overall, this work provides the reader with the most recent state-of-the-art approaches in this field, highlighting key trends and opportunities for more advanced and efficacious HCC treatments.
引用
收藏
页数:33
相关论文
共 140 条
[1]   Cellular Mechanisms of Liver Fibrosis [J].
Acharya, Pragyan ;
Chouhan, Komal ;
Weiskirchen, Sabine ;
Weiskirchen, Ralf .
FRONTIERS IN PHARMACOLOGY, 2021, 12
[2]   The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer [J].
Affo, Silvia ;
Yu, Le-Xing ;
Schwabe, Robert F. .
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 12, 2017, 12 :153-186
[3]   Regulation of flowering time and floral organ identity by a microRNA and its APETALA2-like target genes [J].
Aukerman, MJ ;
Sakai, H .
PLANT CELL, 2003, 15 (11) :2730-2741
[4]   Androgen receptor suppresses vasculogenic mimicry in hepatocellular carcinoma via circRNA7/miRNA7-5p/VE-cadherin/Notch4 signalling [J].
Bao, Shixiang ;
Jin, Shuai ;
Wang, Chunhua ;
Tu, Peipei ;
Hu, Kongwang ;
Lu, Jingtao .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020, 24 (23) :14110-14120
[5]   Trans-splicing and polyadenylation of let-7 microRNA primary transcripts [J].
Bracht, J ;
Hunter, S ;
Eachus, R ;
Weeks, P ;
Pasquinelli, AE .
RNA, 2004, 10 (10) :1586-1594
[6]   Origins and Mechanisms of miRNAs and siRNAs [J].
Carthew, Richard W. ;
Sontheimer, Erik J. .
CELL, 2009, 136 (04) :642-655
[7]   Targeting non-coding RNAs to overcome cancer therapy resistance [J].
Chen, BaoQing ;
Dragomir, Mihnea P. ;
Yang, Chen ;
Li, Qiaoqiao ;
Horst, David ;
Calin, George A. .
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2022, 7 (01)
[8]   lncRNA-POIR promotes epithelial-mesenchymal transition and suppresses sorafenib sensitivity simultaneously in hepatocellular carcinoma by sponging miR-182-5p [J].
Chen, Bryan Wei ;
Zhou, Yue ;
Wei, Tao ;
Wen, Liang ;
Zhang, Yi-bo ;
Shen, Shi-chao ;
Zhang, Jian ;
Ma, Tao ;
Chen, Wen ;
Ni, Lei ;
Wang, Yi ;
Bai, Xue-li ;
Liang, Ting-bo .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2021, 122 (01) :130-142
[9]   SYPL1 overexpression predicts poor prognosis of hepatocellular carcinoma and associates with epithelial-mesenchymal transition [J].
Chen, Dong-Han ;
Wu, Qiu-Wan ;
Li, Xiu-Dong ;
Wang, Shuang-Jia ;
Zhang, Zhi-Ming .
ONCOLOGY REPORTS, 2017, 38 (03) :1533-1542
[10]   APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target [J].
Chen, Huarong ;
Wong, Chi-Chun ;
Liu, Dabin ;
Go, Minnie Y. Y. ;
Wu, Bin ;
Peng, Sui ;
Kuang, Ming ;
Wong, Nathalie ;
Yu, Jun .
THERANOSTICS, 2019, 9 (18) :5246-5260